U.S. Markets closed

Achillion (ACHN) Posts Wider-Than-Expected Q1 Loss, Names CEO

Zacks Equity Research
1 / 2

Simmons First National (SFNC) Tops Q3 Earnings and Revenue Estimates

Simmons First National (SFNC) delivered earnings and revenue surprises of 5.17% and 0.85%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Achillion Pharmaceuticals, Inc. ACHN reported a loss of 15 cents per share for the first quarter of 2018, same as the year-ago loss but wider than the Zacks Consensus Estimate of a loss of 14 cents.

The company generated no revenues in the reported quarter.

Shares of Achillion were down 2.4% on May 2. However, the company's stock have outperformed the industry year to date. The company’s shares have gained 28.1% against the industry’s decrease of 10.9%.

Research and development (R&D) expenses decreased nearly 4.8% from the year-ago period to $14.6 million. The decrease was due to decreased stock-based compensation, lower personnel costs as the February restructuring resulted in reduced number of employees and lower manufacturing and formulation expenses for next generation factor D inhibitor candidate, ACH-5228. This was partially offset by increased costs related to clinical studies of ACH-4471 and ACH-5228 and preclinical costs of ACH-5548.

General and administrative (G&A) expenses decreased 5.9% year over year to $5.3 million due to lower legal and consulting fees.

Restructuring Details

In February 2018, the company announced an operational restructuring plan to focus on its existing factor D inhibitor candidates and reduce expenses. Achillion reduced its workforce by 20% under its restructuring plan. The restructuring is expected to save $10 million in 2018.

Pipeline Update

Achillion is planning to complete a phase II study on its most advanced candidate, ACH-4471, in C3 glomerulopathy (C3G) or immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) in 2018, with interim data planned for the third quarter of 2018. Two more studies are planned for 2018, which will evaluate ACH-4471 in C3G.

Meanwhile, interim data from the ongoing phase II study evaluating ACH-4471 monotherapy in paroxysmal nocturnal hemoglobinuria (“PNH”) is planned for the fourth quarter of 2018. An add-on study is planned for the evaluation of ACH-4471 in combination with Alexion Pharmaceuticals’ ALXN PNH drug, Soliris (eculizumab). Interim data is expected in the fourth quarter of 2018.

The company also targets to complete phase I studies on its two next generation factor D inhibitors – ACH-5228 and ACH-5548 – in the fourth quarter of 2018.

CEO Transition

Concurrent with the earnings release, Achillion announced that Joseph Truitt, current president and chief operating officer, will take the responsibilities of chief executive officer. Milind Deshpande is stepping down from this role. Joseph will also be appointed to the board of directors.

Achillion Pharmaceuticals, Inc. Price, Consensus and EPS Surprise

 

Achillion Pharmaceuticals, Inc. Price, Consensus and EPS Surprise | Achillion Pharmaceuticals, Inc. Quote

Zacks Rank & Stocks to Consider

Achillion Pharma currently carries a Zacks Rank #3 (Hold).

A couple of better-ranked stocks in the biotech sector are Ligand Pharmaceuticals LGND, and Protagonist Therapeutics PTGX. Both the stocks sport a Zacks Rank #1 (Strong Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.

Ligand’s earnings per share estimates moved up from $4.24 to $4.43 for 2018 and remained stable at $5.32 for 2019 over the last 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with an average beat of 24.88%. The company’s shares have rallied 14.6% year to date.

Protagonist Therapeutics’ loss estimates narrowed from $1.68 to 66 cents for 2018 and from $2.43 to $1.26 for 2019 over the last 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with an average beat of 24.95%.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Alexion Pharmaceuticals, Inc. (ALXN) : Free Stock Analysis Report
 
Achillion Pharmaceuticals, Inc. (ACHN) : Free Stock Analysis Report
 
Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report
 
Protagonist Therapeutics, Inc. (PTGX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

  • Why These 3 Top Marijuana Stocks Slumped Today
    Business
    Motley Fool

    Why These 3 Top Marijuana Stocks Slumped Today

    With earnings season hitting a crescendo this week, investors are looking closely at the specific prospects for certain corners of the market, and that's contributing to disparities among the various major benchmarks followed most often by investors. Amid the crosscurrents, marijuana stocks took particularly hard hits, and New Age Beverages (NASDAQ: NBEV), Tilray (NASDAQ: TLRY), and Canopy Growth (NYSE: CGC) were among the worst performers on the day. All three of these stocks have given back some of their gains following the long-awaited legalization of recreational cannabis in the Canadian market last week. In the month leading up to the Oct. 17 start date for legal cannabis sales, New Age Beverages tripled in value, while Tilray had more than doubled since the end of August, and Canopy Growth had seen more modest gains of between 10% and 20%.

  • News
    CNBC

    Here's how much money you should have saved by 50

    Fidelity, the nation's largest retirement-plan provider, recommends having the equivalent of six times your annual salary saved. To get to that number, Fidelity recommends saving 15 percent of your annual income. Make sure to invest these funds instead of leaving them in a traditional low-interest savings account.

  • Business
    Benzinga

    Lockheed Martin's Q3 Earnings Outlook

    On Tuesday, Oct. 23, Lockheed Martin Corporation (NYSE: LMT) will release its latest earnings report. Here is Benzinga's outlook for the company. Earnings and Revenue Based on management's projections, Lockheed Martin analysts model for earnings of $

  • Finance
    CNBC

    Here's the tax bite on $1.6 billion Mega Millions and $620 million Powerball jackpots

    Strategies can be employed to reduce the amount of your win that is taxed, although they are best explored with the help of an experienced tax advisor. While it's anyone's guess who will end up winning the Mega Millions and Powerball jackpots, there's at least one guaranteed recipient of a chunk of the loot — the IRS. With the Mega Millions jackpot at $1.6 billion and Powerball's top prize at $620 million, that tax bill will be hefty even if the winner employs strategies to reduce their taxable income.

  • China Will Open the World's Longest Sea Bridge This Week. A Lot of People Are Unhappy About It
    World
    Fortune

    China Will Open the World's Longest Sea Bridge This Week. A Lot of People Are Unhappy About It

    Later this week, the long-awaited 34-mile sea bridge connecting mainland China to Hong Kong and Macau will finally open. In a ceremony on Tuesday that Chinese president Xi Jinping will reportedly attend, the bridge will officially open. Some critics see the Hong Kong-Zhuhai-Macau Bridge as an attempt by mainland China to tighten its grip on Hong Kong, which is an autonomous region.

  • Former General Electric vice chair on the company's futur...
    Business
    CNBC Videos

    Former General Electric vice chair on the company's futur...

    Beth Comstock, Nike board member and former vice chair of General Electric, weighs in on the future of General Electric under new CEO Larry Culp.

  • Why Nektar Therapeutics Crashed 17.2% Today
    Business
    Motley Fool

    Why Nektar Therapeutics Crashed 17.2% Today

    After delivering a disappointing update on NKTR-214 in cancer patients this summer, Nektar Therapeutics' (NASDAQ: NKTR) shares have been struggling. The company didn't report any news today, so a negative report issued by Plainview LLC this month may be to blamed for its 17.2% tumble today. In February, Bristol-Myers Squibb (NYSE: BMY) inked a blockbuster deal to license rights to NKTR-214 following positive data last year for NKTR-214's use alongside Bristol-Myers' Opdivo.

  • Watch out for ‘dead cat bounce’ in stocks because there’s more pain ahead: Morgan Stanley’s Wilson
    News
    MarketWatch

    Watch out for ‘dead cat bounce’ in stocks because there’s more pain ahead: Morgan Stanley’s Wilson

    October is living up to its infamous reputation as a volatile month for stocks with major indexes down sharply and there is likely more pain ahead for investors, according to one prominent Wall Street analyst. The recent rebound “was a dead cat bounce,” said Michael Wilson, an equity strategist at Morgan Stanley, in a report. After eking out gains last week, the S&P 500 (SPX) is trading below the 200 DMA of 2,768 Monday as stocks struggle for direction with third-quarter earnings cycle picking up pace.

  • 4 Things Aurora Cannabis Did Right Before Its NYSE Debut
    Business
    Motley Fool

    4 Things Aurora Cannabis Did Right Before Its NYSE Debut

    Aurora Cannabis (NASDAQOTH: ACBFF) (TSX: ACB) has sought to make it even easier for U.S. investors to buy its shares by arranging to have its shares listed on the New York Stock Exchange. Beginning tomorrow, Oct. 23, Aurora will join the elite group of cannabis companies whose shares trade on major U.S. exchanges. Getting ready for the increased exposure that a NYSE listing brings takes time and effort, and Aurora Cannabis hasn't wasted any time.

  • Is the New Energy Transfer LP a Buy?
    Finance
    Motley Fool

    Is the New Energy Transfer LP a Buy?

    Last week, Energy Transfer LP (NYSE: ET) emerged on the scene after the former Energy Transfer Equity completed the acquisition of its affiliate Energy Transfer Partners in a unit-for-unit exchange that simplified this complex midstream franchise. The transaction also created a much stronger company that has the financial resources to fund a significant slate of expansion projects. The new Energy Transfer is a behemoth in the midstream sector.

  • SC senator says state law on nuclear construction to be ruled unconstitutional, putting Dominion-SCANA deal at risk
    Finance
    American City Business Journals

    SC senator says state law on nuclear construction to be ruled unconstitutional, putting Dominion-SCANA deal at risk

    A South Carolina circuit judge intends to declare the S.C. Base Load Review Act unconstitutional and has asked lawyers in the cases challenging the law to prepare proposed orders before his final ruling, a state senator says. The expected ruling could force S.C. Electric & Gas to repay customers hundreds of millions of dollars it has already collected to pay its $5 billion share of almost $9 billion spent on the now-abandoned V.C. Summer nuclear plant expansion. It would likely prevent the utility from recovering those costs in the future and could jeopardize Dominion Energy Inc.’s proposed $14.6 billion deal to buy the utility’s parent SCANA Corp, based in Cayce, S.C. S.C. Sen. Brad Hutto said Friday the formal ruling is expected in weeks.

  • Finance
    American City Business Journals

    Microsoft's typical worker makes $168K a year — how that compares with Facebook, Google, PayPal, Box, Salesforce, Intel and other big Bay Area tech employers

    Microsoft Corp. is the latest major Silicon Valley tech employer to reveal just how much its typical employee earns — and how that compares with its top executive. The software giant's median employee pay — almost $168,000 — is high, even by Silicon

  • This Warren Buffett Stock Is Dirt Cheap Right Now
    Business
    Motley Fool

    This Warren Buffett Stock Is Dirt Cheap Right Now

    Warren Buffett has amassed a large portfolio of bank stocks for Berkshire Hathaway (NYSE: BRK-A) (NYSE: BRK-B) with major holdings in Bank of America (NYSE: BAC), Wells Fargo (NYSE: WFC), and American Express (NYSE: AXP), just to name a few of the most well-known and largest investments. Synchrony is a major issuer of store-branded credit cards and also operates a rapidly growing online banking platform.

  • AMD's Q3 Earnings to Benefit from Strong Demand for GPUs
    Business
    Zacks

    AMD's Q3 Earnings to Benefit from Strong Demand for GPUs

    Advanced Micro Devices AMD is set to report third-quarter 2018 results on Oct 24.The company is expected to gain from robust demand of graphic processor units (GPUs), which are now profusely used in industries like gaming, automotive and blockchain.Increasing

  • Meet What Could Be Advanced Micro Devices' Next Billion-Dollar Business
    Business
    Motley Fool

    Meet What Could Be Advanced Micro Devices' Next Billion-Dollar Business

    Advanced Micro Devices (NASDAQ: AMD) CEO Lisa Su said earlier this year that the company plans to achieve "mid-single-digit server unit share" by the end of 2018. The chipmaker's server chip market share crossed 1% at the end of the second quarter. Mercury Research estimates that AMD now commands 1.3% of the server market as compared to just 0.5% earlier.

  • What the Market Missed in Kinder Morgan Inc.'s Results
    Business
    Motley Fool

    What the Market Missed in Kinder Morgan Inc.'s Results

    Kinder Morgan (NYSE: KMI) can't seem to catch a break these days. Despite its completing what management dubbed a "momentous" quarter, shares of the natural gas pipeline giant barely budged this week. It was a head-scratching outcome considering that its financial results came in well above its guidance, which the market seems to have completely missed.

  • Trump's approval rating hits new high ahead of midterms
    ^GSPC
    Yahoo Finance Video

    Trump's approval rating hits new high ahead of midterms

    A new poll shows President Trump's approval rating rose to 47% ahead of the November midterm elections. Yahoo Finance's Seana Smith, Adam Shapiro, Rick Newman, and Andy Serwer discuss.

  • Why AMD Stock Fell 11% on October 19
    Finance
    Market Realist

    Why AMD Stock Fell 11% on October 19

    Semiconductor (SMH) stock Advanced Micro Devices (AMD) fell 11.1% on October 19 to close trading at $23.66. New Street Research analyst Pierre Ferragu has a 12-month price target of $18 for AMD. Ferragu stated, “AMD’s stock price reflects a scenario we don’t believe possible.

  • Investors Dumped Cannabis Stocks after Legalization Last Week
    Finance
    Market Realist

    Investors Dumped Cannabis Stocks after Legalization Last Week

    Cannabis Stocks Getting Dumped after Legalization? Cannabis sector Last week, the overall cannabis sector ended in negative territory. The Horizons Marijuana Life Sciences ETF (HMMJ) lost almost 5.4% of its value, while the Emerging Marijuana Growers

  • 5 Popular Marijuana Stocks I Wouldn't Buy With Free Money
    Business
    Motley Fool

    5 Popular Marijuana Stocks I Wouldn't Buy With Free Money

    Last week on Oct. 17, Canada lifted the curtain on nine decades of prohibition and legalized recreational marijuana for adults. Given the notable surge in pot stocks since the beginning of 2016, it's pretty evident that Wall Street and investors expect the industry to be a resounding success. With that being said, there are a handful of marijuana stocks -- some quite popular -- that I simply wouldn't buy, even if I were given free money to do so.

  • Why Pot Stocks Canopy Growth, Cronos Group, and Tilray Are Cratering Today
    Business
    Motley Fool

    Why Pot Stocks Canopy Growth, Cronos Group, and Tilray Are Cratering Today

    Canadian pot stocks are getting hit hard across the board today. As of 1:21 p.m. EDT, for example, shares of Canopy Growth Corporation (NYSE: CGC) and Cronos Group (NASDAQ: CRON) were both down by 11.2%, whereas Tilray's(NASDAQ: TLRY) stock had fallen by 14.4%. Canopy, Cronos, and Tilray all seem to be succumbing to a so-called "sell the news" event.

  • 3 Dividend Stocks to Fund Your Retirement Nest Egg
    Business
    Motley Fool

    3 Dividend Stocks to Fund Your Retirement Nest Egg

    Dividend stocks play a key role in a good retirement portfolio, but investing indiscriminately in companies just because they offer a big yield or have a recent history of payout growth will likely cause your portfolio's performance to fall short of its

  • Aurora Cannabis prepares for NYSE debut on Oct. 23
    Finance
    Yahoo Finance Canada

    Aurora Cannabis prepares for NYSE debut on Oct. 23

    One of Canada’s largest marijuana producers is gearing up for its big debut on the New York Stock Exchange on Tuesday, Oct. 23. Edmonton-based Aurora Cannabis will be the third major Canadian cannabis company to go public in the U.S., where marijuana is still an illegal substance in most states. Aurora will be following in the steps of Tilray, which became the first U.S. marijuana IPO in July, and Canopy Growth, which debuted in the U.S. markets in May.

  • Which Canadian Marijuana Stock Will Enjoy a Bigger Bump From Its NYSE Listing -- Aphria or Aurora?
    Business
    Motley Fool

    Which Canadian Marijuana Stock Will Enjoy a Bigger Bump From Its NYSE Listing -- Aphria or Aurora?

    Maybe Wall Street should be called "Weed Street." Big Canadian marijuana grower Canopy Growth listed its stock on the New York Stock Exchange (NYSE) earlier this year. Aurora Cannabis (NASDAQOTH: ACBFF) begins trading on the NYSE on Tuesday, Oct. 23. Aphria (NASDAQOTH: APHQF) filed last week to list its stock on the NYSE.

  • Suze Orman has a killer question for your retirement
    Business
    MarketWatch

    Suze Orman has a killer question for your retirement

    Suze Orman is one of those singular personalities in the financial business who seems to be right on the pulse of everyone she meets. She’s written books, starred in her own television show and made innumerable appearances in person. Like Oprah